CN Patent

CN119776509A — Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途

Assigned to Shengyuan Zetong Shanghai Pharmaceutical Co ltd · Expires 2025-04-08 · 1y expired

What this patent protects

本发明发现了Ndufa10基因和/或S1pr4基因突变和肌营养不良发病间的相关性。本发明提供了Ndufa10基因和S1pr4基因突变在肌病诊断和预测中的用途。本发明还提供了Ndufa10基因和S1pr4基因单突变和双突变诱导的肌营养不良动物模型及造模方法。本发明具有在肌营养不良疾病诊断和治疗药物筛选中应用的前景。

USPTO Abstract

本发明发现了Ndufa10基因和/或S1pr4基因突变和肌营养不良发病间的相关性。本发明提供了Ndufa10基因和S1pr4基因突变在肌病诊断和预测中的用途。本发明还提供了Ndufa10基因和S1pr4基因单突变和双突变诱导的肌营养不良动物模型及造模方法。本发明具有在肌营养不良疾病诊断和治疗药物筛选中应用的前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN119776509A
Jurisdiction
CN
Classification
—
Expires
2025-04-08
Drug substance claim
No
Drug product claim
No
Assignee
Shengyuan Zetong Shanghai Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.